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ABSTRACT 23 
Little is known regarding metabolic benefits of weight loss (WL) on the metabolically healthy obese 24 
(MHO) patients. We aimed to examine the impact of a lifestyle weight loss (LWL) treatment on the 25 
plasma metabolomic profile in MHO individuals. Plasma samples from 57 MHO women allocated 26 
to an intensive LWL treatment group (TG, hypocaloric Mediterranean diet and regular physical 27 
activity, n = 30) or to a control group (CG, general recommendations of a healthy diet and physical 28 
activity, n = 27) were analyzed using an untargeted 1H NMR metabolomics approach at baseline, 29 
after 3 months (intervention), and 12 months (follow-up). The impact of the LWL intervention on 30 
plasma metabolome was statistically significant at 3 months but not at follow-up and included higher 31 
levels of formate and phosphocreatine and lower levels of LDL/VLDL (signals) and trimethylamine 32 
in the TG. These metabolites were also correlated with WL. Higher myo-inositol, methylguanidine, 33 
and 3-hydroxybutyrate, and lower proline, were also found in the TG; higher levels of hippurate and 34 
asparagine, and lower levels of 2-hydroxybutyrate and creatine, were associated with WL. The 35 
current findings suggest that an intensive LWL treatment, and the consequent WL, leads to an 36 
improved plasma metabolic profile in MHO women through its impact on energy, amino acid, 37 
lipoprotein, and microbial metabolism. 38 




Recent studies have shown that even within the obese phenotype, cardiometabolic risk may not 43 
necessarily vary primarily in relation to weight or body mass index (BMI) but to other subclinical 44 
alterations.1,2 In this sense, there is a subset of obese individuals with lower risk of CVD or all-cause 45 
mortality,3,4 which has been referred to as the “obese healthy paradox”.5 Although there is currently 46 
a lack of consensus on its definition, it has been suggested that metabolically healthy obese (MHO) 47 
individuals have ≤ 1 of the metabolic syndrome (MetS) criteria in addition to waist circumference 48 
(WC) ≥ 102 cm for men and ≥ 88 cm for women, that is, hypertension, hypertriglyceridaemia, 49 
hyperglycaemia or diagnosis of diabetes, and dyslipidaemia in comparison to their metabolically 50 
unhealthy obese (MUO) counterparts.6 In addition, other parameters, such as insulin sensitivity, and 51 
inflammatory markers, such as tumor necrosis factor alpha (TNF-α), have been suggested for 52 
inclusion in the definition of MHO.5,7 In the face of a lack of consensus for MHO definition, recent 53 
metabolomic studies have contributed with a better characterization of the metabolic signatures of 54 
this phenotype.8 The prevalence of MHO varies widely, partly depending on definition criteria, but 55 
seems to be higher in women and in people of younger ages and also dependent on region and 56 
lifestyle.9,10 On the other hand, long-term studies have suggested that MHO is a transient state 57 
toward MUO,11,12 indicating that without proper care, MHO individuals may increase their risk of 58 
developing T2D and CVD. Furthermore, since a decisive feature of MHO is the absence of visceral 59 
fat accumulation,13 the promotion of lifestyle interventions aimed at minimizing visceral fat 60 
accumulation is of fundamental importance from a public health perspective. Although diet and 61 
physical activity are well-known and modifiable CVD risk factors, their potential beneficial impact 62 
on MHO under controlled conditions has only recently received attention.14,15 Recent studies have 63 
demonstrated that intensive lifestyle weight loss (LWL) interventions based on calorie restriction and 64 
physical activity were effective as means of improving body composition and several cardiometabolic 65 
risk markers in obese individuals.16−18 In this sense, for instance, the adherence to healthy dietary 66 
patterns such as the Mediterranean diet (MedDiet) has been widely recommended for reducing the 67 
incidence and lowering the prevalence of MetS and its components.19 Currently, a better 68 
understanding of how a LWL intervention impacts on the metabolism of obese individuals has been 69 
little addressed by the use of metabolomics. For example, in a recent study, Khakimov and colleagues 70 
reported that as result of a LWL intervention study with a healthy New Nordic Diet, participants with 71 
greater weight loss differed in their plasma metabolite composition including metabolites related to 72 
energy metabolism and food intake.20 In the current study, we therefore aimed to (i) determine the 73 
impact of an intensive lifestyle treatment for weight loss (based on a hypocaloric Mediterranean diet 74 
and regular physical activity) in comparison to a control group (general recommendations for a 75 
cardiometabolic healthy diet and physical activity) on the plasma metabolome, measured by 76 
untargeted 1H NMR metabolomics, in women defined as MHO and to (ii) investigate the associations 77 
of WL and changes in other cardiometabolic risk markers with changes in metabolome after 78 
following the intervention. 79 
EXPERIMENTAL SECTION 80 
Participants and Study Design 81 
A total of 115 women aged 35−55 defined as MHO were recruited from four health centers in the 82 
Malaga District of the Andalusian Health Service (Spain).21 Diagnosis of metabolic health status 83 
was based on the general criteria proposed by the International Diabetes Federation (IDF).22 Besides 84 
obesity (BMI ≥ 30 kg/m2), participants were included if they had ≤1 of the following cardiovascular 85 
risk factors: elevated fasting glucose levels (plasma glucose ≥100 mg/dL), elevated blood pressure 86 
(systolic ≥135 or diastolic ≥85 mmHg or use of antihypertensive drugs), elevated triglycerides (≥150 87 
mg/dL or treatment with lipid-lowering medication), or decreased high-density-lipoprotein 88 
cholesterol (HDL) (<50 mg/dL). The exclusion criteria were previous diagnosis of diabetes, 89 
pregnancy or planning to become pregnant during the study, CVD, presence of any severe chronic 90 
illness, alcohol or drug abuse, or undertaking a WL program that included physical activity or diet in 91 
the past three months. Participants were randomly allocated to either the control (n = 48) or the 92 
treatment group (n = 67). Participants assigned to the control group received general 93 
recommendations on a cardiometabolic healthy diet and physical activity. Participants in the 94 
treatment group received an intensive intervention program for losing weight, consisting of a 95 
hypocaloric MedDiet and regular physical activity. The MedDiet included the intake of extra virgin 96 
olive oil and nuts but with an overall energy restriction of about 600 kcal (approximately 30% of 97 
estimated energy requirements). The distribution of the target daily total caloric intake for the 98 
intervention group was: 35−40% fats (8− 10% saturated fatty acids; SFA), 40−45% carbohydrates 99 
with low glycemic index, and 20% protein. Adherence to the MedDiet was measured at baseline and 100 
after 12 months of follow-up by using a 16-item screener from the PREDIMED study23 and adapted 101 
to assess hypocaloric MedDiet. In the physical activity program, participants were encouraged to 102 
practice a minimum of 150 min/wk of walking. Participants allocated to the treatment group attended 103 
visits with a certified nutritionist every week during the first 3 months, and then once at 12 months, 104 
whereas individuals in the control group attended these visits only after 3 and 12 months of the study. 105 
All participants provided written informed consent. The study was conducted in accordance with the 106 
guidelines set out in the Declaration of Helsinki, and all protocols were approved by an Ethics and 107 
Research Committee (Comite Coordinador de Etica de la Investigacion Biomedica de Andalucia). 108 
This study was registered at https://www.isrctn.com/ as ID ISRCTN88315555. 109 
Clinical Measurements and Sampling 110 
Anthropometric measurements, including weight, height, waist circumference (WC), and BMI, were 111 
taken by trained nurses at baseline and after 3 and 12 months, and blood pressure measurements were 112 
taken at baseline and at 12 months. Fasting blood samples were collected in tubes containing EDTA 113 
on the day of enrolment and after 3 and 12 months. Analyses of fasting glucose and lipid profile were 114 
conducted according to routine methods and within 12 h of sample collection. For metabolomics 115 
analysis, plasma samples were collected at the same time points, aliquoted, and immediately stored 116 
at −80 °C until analysis. 117 
NMR Metabolomics 118 
Sample Preparation. Plasma samples were thawed at 4 °C, briefly spun down and 150 μL was mixed 119 
with 150 μL of ultrapure water and 600 μL of pure cold (−20 °C) methanol in 96-deep-well plates. 120 
The mixtures were vortexed, incubated (first at 12 °C, 800 rpm for 10 min and then at −20 °C for 30 121 
min), and centrifuged (2250g at 4 °C for 60 min) to precipitate proteins. Supernatants (600 μL) were 122 
transferred into clean deep-well plates and lyophilized at −4 °C for 16 h. Dried samples were washed 123 
in 50 μL of deuterated methanol (MeOD) and again lyophilized to remove the excess of non- MeOD. 124 
The new pellets were reconstituted in 200 μL of buffer (37.5 mM sodium phosphate, pH 6.95, 100% 125 
D20, 0.02% NaN3, 0.25 mM DSS-d6 and 1 mM imidazole) and shaken in an Eppendorf 126 
ThermoMixer at 800 rpm, 22 °C, for 30 min. Samples in buffer (180 μL) were transferred into 3 mm 127 
SampleJet NMR tubes using a SamplePro L liquid handling robot (Bruker BioSpin, Rheinstetten, 128 
Germany). 129 
1H NMR Spectroscopy. All 1H NMR experiments were performed on an Oxford 800 MHz magnet 130 
equipped with a Bruker Avance III HD console and a 3 mm TCI cryoprobe using a water suppression 131 
pulse program. Each spectrum was acquired at 298 K applying 128 scans, a spectral width of 20 ppm, 132 
a data size of 65 K points, an acquisition time of 2.05 s and a relaxation delay of 3 s. Spectra were 133 
processed using TopSpin 3.5pI6 (Bruker GmbH, Rheinstetten, Germany). Processed spectral data 134 
were imported into MatLab (Math- Works Inc., Natick, MA) using in-house written scripts. 135 
Alignment was achieved using a combination of an in-house peak reference picking function and the 136 
“speaq” R-package (version 1.2.1).24 137 
Statistical Analyses. All statistical data analyses were performed within the R environment (version 138 
3.3.1). Differences in anthropometric and clinical variables at baseline and after 3 and 12 months 139 
were assessed by independent or paired Student’s t tests according to comparisons between or within 140 
groups, respectively. Data are expressed as mean ± SD, unless otherwise stated. To determine 141 
discriminant metabolites between control and treatment groups at 3 of intervention and at 12 months 142 
of follow-up, we used NMR data of differences in metabolome between baseline and each time point 143 
(3 or 12 months) and conducted a supervised analysis based on random forest (RF) modeling within 144 
an in-house-developed repeated double crossvalidation framework (rdCV).25,26 In brief, the in-145 
house double CV procedure, which has been successfully used in untargeted metabolomics27 and 146 
microbiota analysis,28 consists of nested loops (outer “testing” and inner “calibration” loops) to 147 
reduce bias from overfitting models to experimental data.25 Feature ranking and selection are 148 
performed within the inner loop, to minimize statistical overfitting, by iteratively turning over 149 
successively fewer features, removing from each step in the loop the 10% least informative 150 
features.27 The rdCV procedure was subjected to 30 repetitions to improve modeling accuracy and 151 
with misclassification as the fitness function. The overall validity and degree of overfitting of models 152 
were assessed by permutation analysis, following the same rdCV procedure and by reporting the 153 
cumulative probability of actual model fitness within a population of fitness measures of randomly 154 
permuted classifications (n = 200) based on the assumption of Student’s t-distribution. The 155 
assumption was confirmed by visual inspection of the histograms of permuted distributions. 156 
Secondary analyses of associations of changes in metabolome with changes in weight or other clinical 157 
parameters were performed using both the control and treatment groups together, as well as in 158 
treatment group alone, by partial leastsquares (PLS) regression within a similar rdCV framework. 159 
The quality of each model was evaluated by the R2 (the proportion of the variance of the response 160 
variable that is explained by the model) and Q2 (the predictive ability) parameters. Permutation tests 161 
(n = 200) were performed similarly to the analysis above, but with Q2 as the fitness measure. 162 
Differences in changes of metabolites between groups after the intervention were calculated by fold 163 
change (FC), taking the control group as reference, and assessed by independent Student’s t tests. 164 
The FC here was calculated as follows: FC = ΔTreament/ΔControl, where ΔTreament and Δ165 
Control denote the differences between the NMR intensities of metabolites at either 3 or 12 months 166 
and at baseline, for treatment and control groups, repectively. Correlations between significant 167 
metabolites selected from multivariate modeling of weight change after the intervention were 168 
calculated by Spearman’s rank correlation (“Hmisc” R-package version 4.0−2). A false discovery 169 
rate (FDR) test based on Benjamini−Hochberg procedure29 was applied to adjust the pvalue for 170 
multiple comparisons in univariate and correlation analyses. 171 
Metabolite Identification. Identification of metabolites was achieved by matching experimental 172 
NMR spectra with those stored in Chenomx NMR Suite 8.2 software (Chenomx Inc., Canada) in 173 
combination with an in-house R script for statistical correlation spectroscopy30 and through 174 
searching in the Human Metabolome Database (HMDB) compound reference library.31 175 
RESULTS 176 
Baseline Characteristics of the Participants 177 
Of the 115 participants recruited, 58 were excluded due to dropout or failure to show at all visits (n 178 
= 43), illness (n = 6), unavailable sample at some time point (at baseline, 3 or 12 months, n = 7), or 179 
change of residence (n = 2). Therefore, 57 participants were included in the present data analyses. 180 
Anthropometric measures and clinical parameters at baseline and after 3 and 12 months are presented 181 
in Table 1. At baseline, MHO participants had a mean (±SD) age of 45.1 ± 3.45 y and a BMI of 35.8 182 
± 4.93 kg/m2. No differences between the control and treatment groups were observed at baseline 183 
regarding menopause, weight, waist circumference, blood pressure, glycaemia, or lipid profile (Table 184 
1). 185 
Changes in Anthropometric and Clinical Measurements 186 
At both 3 and 12 months, the treatment group showed greater WL and more pronounced reductions 187 
in BMI and WC than the control group (Table 1). Compared to baseline, both groups showed a 188 
decrease in total cholesterol and changes in HDL at 3 and 12 months. In particular, at 3 months, the 189 
levels of HDL were decreased in the treatment group and increased in the control group. Moreover, 190 
at 3 months, only participants in the treatment group showed decreases in LDL cholesterol and at 12 191 
months decreases in SBP, glucose, and triglycerides, whereas at 12 months, only the control group 192 
showed decreases in LDL (Table 1). 193 
Multivariate Modeling of Intervention and Weight Change 194 
The classification of participants as treatment or control group based on the changes in metabolome 195 
is shown in Figure 1. The rdCV-RF models resulted in a high correct classification rate (86%, 196 
permutation test p < 0.001) of the individuals at 3 months and lower correct classification rate (65%, 197 
permutation test p < 0.05) at 12 months (Figure 1; Supporting Information, Figure S-1). With the 198 
exception of weight change, changes in other clinical parameters were not significantly associated 199 
with changes in the metabolome (data not shown). The rdCVPLS regression of weight change based 200 
on changes in metabolome resulted in moderate associations when all participants (R2 = 0.630, Q2 = 201 
0.257; permutation test p < 0.001), or only participants in the treatment group (R2 = 0.744, Q2 = 202 
0.298; permutation test p < 0.001), were included in the analysis (Figure 2; Supporting Information, 203 
Figure S-2). 204 
Modulatory Effect of Intervention on Plasmatic Metabolites 205 
Changes in metabolome after 3 months of intervention included higher levels in the treatment group 206 
of 3- hydroxybutyrate (3-HB), formate, methylguanidine, myoinositol, and phosphocreatine, as well 207 
as lower levels of LDL/VLDL signals, proline, trimethylamine (TMA), and three unassigned 208 
compounds (U3.32, U4.35, and U6.40) (Table 2). Absolute FC in 3-HB, methylguanidine, 209 
phosphocreatine, myo-inositol, proline, U4.35, and U6.40 were ≥2 (two-times or more) higher in the 210 
treatment group than in the control group. Because of the poor multivariate classification between 211 
groups at 12 months, discriminant metabolites at 3 months were further investigated by t test at 12 212 
months of follow-up (Table 2). From this analysis, differences between the treatment and control 213 
groups at 12 months were only observed in U3.32 (p < 0.05) and phosphocreatine (p < 0.05). 214 
However, compared to at 3 months, fold changes in these metabolites at 12 months indicated a more 215 
accentuated change in U3.32 and a change from upregulation to downregulation in phosphocreatine. 216 
Changes in Metabolome Associated with Weight Loss 217 
A total of 11 metabolites were moderately associated with a change in weight from baseline in both 218 
groups at 3 months (Table 3). Keeping in mind that an association of metabolites with WL was 219 
established as an inverse association with weight change (i.e., a positive association with weight 220 
change means an inverse association with WL), WL was inversely associated with 2-hydroxybutyrate 221 
(2-HB), creatine, LDL/VLDL signals, TMA, and three unknown compounds (U.sugar, U2.96, and 222 
U3.32) and directly associated with asparagine, formate, hippurate, and phosphocreatine. 223 
Interestingly, from this model, the changes in formate, phosphocreatine, LDL/VLDL signals, TMA, 224 
and U3.32 were found to be in the same direction as those observed in the previous model with 225 
treatment (Figure 3). 226 
DISCUSSION 227 
Using untargeted 1H NMR-based metabolomics and multivariate modeling, we were able to 228 
determine changes in the plasma metabolome associated with a LWL treatment based on a 229 
hypocaloric diet and physical activity in MHO women. Within this context, we further investigated 230 
the association of WL with changes in the metabolome. As expected, compared to the control group, 231 
individuals in the treatment group underwent greater WL. It is important to highlight that participants 232 
of the current metabolomics study were a subpopulation of other larger study aimed to assess the 233 
effect of WL on cardiometabolic risk markers.21 Findings in the present study regarding changes in 234 
clinical parameters were similar to that larger study. Consequently, the discussion in the current work 235 
focuses on the impact of LWL intervention on the plasma metabolome. Differences in the plasma 236 
metabolome between the treatment and control groups were more pronounced at 3 than at 12 months 237 
(Figure 1; Supporting Information, Figure S-1). One reason could be the similar WL achieved during 238 
the period between the third and 12th months after beginning the intervention (Table 1) or 239 
compensatory mechanisms that attenuated the effects at 12 months. Among cardiometabolic risk 240 
markers, only weight change was associated with the changes in metabolome after 3 months of the 241 
study (Figure 2; Supporting Information, Figure S-2). We found distinct and common metabolites 242 
associated in the same direction with the intervention and WL (Figure 3), which together reflect a 243 
positive impact of an intensive LWL intervention on the metabolism of energy, amino acids, 244 
lipoproteins, and microbiota. For instance, the higher 3-HB observed in the treatment group than in 245 
the control group is consistent with previous studies on weight loss.32,33 High circulating levels of 246 
ketone bodies are observed under energyrestricted metabolic states caused by fasting and caloric 247 
restriction, through increased lipolysis of fatty acids in liver mitochondria.34 Therefore, the increase 248 
of 3-HB in treatment may reflect energy homeostasis through increased lipid oxidation.35 249 
Interestingly, 2-HB, a well-known early biomarker of impaired glucose regulation in non-T2D 250 
individuals,36 was found to decrease with WL. We therefore speculate that as a result of WL, the 251 
MHO individuals may have decreased their risk of developing T2D.37 The association of proline and 252 
asparagine with treatment and WL, respectively, reflects impacts on amino acid metabolism. The 253 
lower levels of proline in the treatment group than in the control group are in line with previously 254 
reported data, indicating that both caloric restriction33 and increased physical activity38 result in 255 
lower circulating proline in obese individuals. Moreover, previous studies have also shown an 256 
association between long-term successful WL and lower plasma proline levels.39 However, this was 257 
not supported in the present study since proline was not directly associated with WL. The positive 258 
association between asparagine and WL found in our study is consistent with previous reports, which 259 
have shown an inverse association between this amino acid and obesity.40,41 Circulating levels of 260 
asparagine can be obtained from dietary sources or synthesized from endogenous oxaloacetate via 261 
aspartate. Studies conducted in animal models have demonstrated that supplementation with aspartate 262 
and asparagine increased the glucose uptake and glycogen content in skeletal muscle, possibly 263 
through the incorporation of glucose transporters type 4 or vesicles into the glycogen complex.42 We 264 
therefore speculate that along with WL, an increase of asparagine may be associated, in part, with an 265 
improved glucose homeostasis. However, future studies are warranted to better determine the 266 
functional role of asparagine in WL. Taken together, the observed associations of 3-HB, 2- HB, and 267 
asparagine with the current LWL intervention and WL strongly suggest a positive impact on glucose 268 
homeostasis in the MHO phenotype, which could also be interpreted as a decreased risk of T2D. Also 269 
related to amino acid metabolism, we found that phosphocreatine increased with both treatment and 270 
WL, whereas creatine decreased with WL. Creatine is mainly produced in the liver and skeletal 271 
muscle from glycine and arginine and can further be phosphorylated to form phosphocreatine by the 272 
enzymatic action of creatine kinase (CK).43 We therefore speculate that the contrasting association 273 
of creatine and phosphocreatine with WL may be related to a modulatory effect of WL on CK activity. 274 
Recent studies showing significant associations of CK with obesity44,45 and weight loss46 may 275 
support this hypothesis. With regard to lipoprotein metabolism, we found lower intensity of signals 276 
corresponding to LDL/VLDL in the treatment than in the control group and this was also inversely 277 
associated with WL, which is consistent with previous studies47 and probably related to increased 278 
expression of LDL receptor and lipoprotein lipase.48 Similar findings regarding the profile of these 279 
lipoprotein fragments associated with WL were recently reported by Rodriguez-Garcia et al. in this 280 
cohort, albeit using a different analytical approach.21 The contribution of four microbial metabolites, 281 
that is, formate, hippurate, methylguanidine, and TMA, to either treatment or weight change models 282 
strongly supports previous reports that highlight the role of host-microbiota interactions in body 283 
weight composition and WL; the latter being promoted by either a LWL intervention based on diet49 284 
or bariatric surgery.50 For example, TMA, an intermediate metabolite from the microbial metabolism 285 
of dietary carnitine and choline, decreased after LWL and WL in the present study. Trimethylamine 286 
is oxidized by hepatic flavin-containing monooxygenases to form trimethylamine-N-oxide (TMAO), 287 
which has been shown to be both proatherogenic and associated with cardiovascular disease 288 
risk.51,52 We hypothesize that the lower levels of TMA associated with treatment and WL are related 289 
to either a lower intake of its dietary precursors (i.e., eggs and meat)52,53 or modulation of choline 290 
and carnitine metabolism, and consequently point to a lower risk of CVD due to a likely reduced 291 
synthesis of TMAO. The observed treatment-related changes in these microbial metabolites may be 292 
related with dietary intake. In the current study, however, data on food intake at 3 months that would 293 
have allowed us to better establish this relationship were unfortunately lacking. Other unidentified 294 
metabolites, including unassigned signals corresponding to sugars, were found to be related to 295 
treatment and WL (Tables 1 and 2). Of particular interest is the unknown U3.32, which was not only 296 
found to be related to treatment and WL at 3 months, but also remained significant in the treatment 297 
group at 12-month follow-up. Further research to identify this compound to understand its role in WL 298 
in the short and long-term is needed. The high number of subjects misclassified at 12 months suggests 299 
a larger similarity in the changes in metabolome between groups, presumably due to either loss of 300 
compliance or adaptation to changes after the first 3 months in the treatment group. Several factors, 301 
including physiological, behavioral, and environmental ones, are key to both compliance and dropout 302 
in long-term programs for WL.54 It is well documented that although lifestyle interventions can be 303 
effective for long-term WL and improvements on cardiometabolic markers, maximum WL is 304 
normally achieved between 1 and 6 months, followed by variable weight maintenance or weight 305 
regain.55 However, in the present study, no differences in WL could be observed within the groups 306 
from 3 to 12 months, thereby suggesting a maintenance phase. Therefore, based on the poor 307 
multivariate predictions at 12 months combined with the maintained WL between 3 and 12 months, 308 
we hypothesize that a metabolic adaptation occurs during this maintenance stage. To the best of our 309 
knowledge, however, there are no reports on this type of metabolic/metabolome adaptation as a result 310 
of longer-term WL interventions. Furthermore, although participants were defined a priori as 311 
belonging to MHO, the combined results at 3 months, in terms of changes in clinical parameters and 312 
metabolome, indicate that the current weight loss intervention caused shifts toward a healthier 313 
phenotype with reduced risk of CVD. However, the positive metabolic regulations appeared to be 314 
attenuated in the longer term, even though weight loss was maintained. The reasons for this 315 
attenuation remain unclear. We recognize that our study has a number of limitations and strengths. 316 
For instance, the sample size is relatively small and the study participants were exclusively 317 
Caucasian, women, and middle-aged. Thus, we cannot extrapolate our conclusions to the general 318 
population. In this sense, it would be interesting, for example, to determine the effect of a LWL in 319 
MUO individuals as well as in men. Another limitation of our study was that compliance of physical 320 
activity practice during all study and of MedDiet at 3 months, in both groups, was not measured, thus 321 
leading to a lack of information regarding adherence to parts of the applied intervention. We, 322 
however, hypothesize that due to the larger WL at both 3 and 12 months, the practice of physical 323 
activity and intake of hypocaloric MedDiet were significantly higher in treatment than in control 324 
group, as expected. On the other hand, because we were not able to assign the identity of unknown 325 
compounds, potentially important information about metabolic perturbations in relation to 326 
intervention and WL was unavailable. Future research aimed at identifying these unknown 327 
compounds is warranted. As was also pointed out above, our study also had several strengths. The 328 
current findings demonstrate that even with a relative healthy condition, the adoption of LWL is 329 
always a recommended strategy to reduce the cardiovascular risk and complications in obese 330 
individuals. This would be supported, for instance, with the observed inverse association between 331 
WL and an early biomarker of impaired glucose regulation (2-HB), suggesting a modulatory effect 332 
of WL on the diabetes risk. Furthermore, the untargeted workflow employed peak picking instead of 333 
binning, thereby expanding and improving the available information content in the original data. The 334 
multivariate modeling procedure and validation framework employed a data-driven, robust approach 335 
to maximize information density while minimizing the likelihood of false-positive findings, thereby 336 
focusing automatically on the most relevant metabolic perturbations in relation to the WL 337 
intervention.27 Finally, our findings reinforce the utility of metabolomics in the identification of 338 
biomarkers (beyond clinical parameters) of LWL interventions in individuals with moderate risk of 339 
CVD. These biomarkers could be used in future research as additional targets of LWL interventions. 340 
CONCLUSIONS 341 
In conclusion, using untargeted 1H NMR metabolomics and multivariate modeling, we determined 342 
that the impact on plasma metabolome of MHO women after a lifestyle intervention for weight loss, 343 
based on hypocaloric Mediterranean diet and regular physical activity, was driven by changes in 344 
amino acid, lipoprotein and microbial metabolism. Furthermore, we found that changes in the 345 
metabolome were associated with weight loss within the frame of the same intervention. Taken 346 
together, the lifestyle intervention and weight loss regulated plasma metabolome of MHO toward a 347 
healthier phenotype. Such regulations were only observed at 3 months. Although weight loss was 348 
maintained at 12 months, the metabolic changes driven by intervention were substantially attenuated 349 
at 12 months, suggesting metabolic adaptation. The inverse association between WL and 2-HB, in 350 
conjunction with observed changes in other energy-related metabolites, could be interpreted as a 351 
decreased risk of T2D as an effect of the LWL treatment. Future research on metabolomic changes 352 
and adaptation in long-term studies is warranted. 353 
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Schröder, H.; Fito, M.; Estruch, R.; Martinez-Gonzalez, M. A.; Corella, D.; Salas-Salvado, J. A 481 
Short Screener Is Valid for Assessing Mediterranean Diet Adherence among Older Spanish Men and 482 
Women. J. Nutr. 2011, 141, 1140. (24) Vu, T. N.; Valkenborg, D.; Smets, K.; Verwaest, K. A.; 483 
Dommisse, R.; Lemière, F.; Verschoren, A.; Goethals, B.; Laukens, K. An Integrated Workflow for 484 
Robust Alignment and Simplified Quantitative Analysis of NMR Spectrometry Data. BMC Bioinf. 485 
2011, 12, 405. 486 
(25) Filzmoser, P.; Liebmann, B.; Varmuza, K. Repeated Double Cross Validation. J. Chemom. 2009, 487 
23 (4), 160−171. (26) Westerhuis, J. A.; Hoefsloot, H. C. J.; Smit, S.; Vis, D. J.; Smilde, A. K.; van 488 
Velzen, E. J. J.; van Duijnhoven, J. P. M.; van Dorsten, F. A. Assessment of PLSDA Cross Validation. 489 
Metabolomics 2008, 4 (1), 81−89. 490 
(27) Hanhineva, K.; Brunius, C.; Andersson, A.; Marklund, M.; Juvonen, R.; Keski-Rahkonen, P.; 491 
Auriola, S.; Landberg, R. Discovery of Urinary Biomarkers of Whole Grain Rye Intake in Free-492 
Living Subjects Using Nontargeted LC-MS Metabolite Profiling. Mol. Nutr. Food Res. 2015, 59 (11), 493 
2315−2325. 494 
(28) Buck, M.; Nilsson, L. K.; Brunius, C.; Dabiré, R. K.; Hopkins, R.; Terenius, O. Bacterial 495 
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FIGURES 581 
 582 
Figure 1. Predictive classification of individuals according to intervention group at 3 and 12 months. 583 
Random forest modeling was conducted applying a repeated double cross-validation algorithm as 584 
described in the Experimental section. Individual classification probability from each submodel (n = 585 
30) is colored in red for control group (columns 1−27) and in green for treatment group (columns 28586 
−57). Averaged classification probability per individual according to group is shown in larger size 587 
and similar color. Misclassified individuals are marked by a black circle. 588 
 589 
Figure 2. Regression analyses between actual and predicted weight change from baseline to 3 months 590 
according to rdCV-PLS modeling in control and treatment groups combined (A) and in treatment 591 
group alone (B). 592 
 593 
Figure 3. Distinct and common metabolic regulations caused by treatment or associated with weight 594 
loss in MHO participants. Metabolite’s class is enclosed in parentheses; ↑ and ↓ denote up- and 595 
down-regulation, respectively. Abbreviations: 3-HB, 3-hydroxybutyrate; 2-HB, 2-hydroxybutyrate; 596 
AA, amino acids; FA, fatty acids; HD, hypocaloric diet; LDL, low-density lipoprotein cholesterol; 597 
PA, physical activity; VLDL, very low-density lipoprotein cholesterol; TMA, trimethylamine 598 





    
